Business Wire

NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

Share

NEC OncoImmunity AS (NOI) today announced it has published a study that describes the use of its artificial intelligence (AI) based neoantigen prediction technology to demonstrate that high neoantigen quality in conjunction with infiltration of immune cells in tumors correlates with improved progression free survival (PFS) in sarcoma patients treated with immune checkpoint inhibitors.

The authors sequenced tumor samples and blood from patients who participated in the pivotal SARC028 clinical trial and received the pembrolizumab checkpoint inhibition therapy. They then used their AI-based neoantigen prediction technology, the NEC Immune Profiler, to investigate whether high quality neoantigens in cooperation with the immune cell composition in the tumor improved PFS. Their analysis suggested that the presence of high quality neoantigens together with T cells in tumors are key prognostic markers of PFS. This trend was not observed with the combined presence of T cells and high tumor mutational burden, highlighting the importance of accurate and clinically relevant neoantigen prediction.

The study which was published in Frontiers in Immunology was performed in collaboration with Oslo University Hospital (OUH) in addition to other collaborators from the SARC028 sarcoma clinical trial, including MD Anderson and the University of Pittsburgh Medical center. Professor Ola Myklebost, one of the senior authors in the paper at OUH, and who is currently serving as Professor of molecular oncology at the University of Bergen said:

“The heterogeneity and rarity of sarcomas makes it challenging to develop successful therapies for sarcoma patients. This research addresses the need to develop further insights into potential biomarkers that may determine which patients are most likely to benefit from precision immunotherapy in such rare cancers.”

While the findings are promising, the published study acknowledges the need for further research and validation with larger sample sizes. The NOI researchers believe that AI can play a future role in guiding future personalized medicine and cancer diagnostics, ultimately improving outcomes for patients with cancer.

“Although our findings are based on a small number of patients, and this trend certainly needs to be corroborated in future studies, this work is potentially an important demonstration of how AI may guide future clinical trials and biomarker discovery. These and future advances in this field may lead to improved clinical outcome for patients suffering from rare cancers treated with cancer immunotherapy,” said Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity, and a senior author in the study.

References

Title: The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition

Authors: Irantzu Anzar, Brandon Malone, Pubudu Samarakoon, Ioannis Vardaxis, Boris Simovski, Hugues Fontenelle, Leonardo A Meza-Zepeda, Richard Stratford, Emily Z Keung, Melissa Burgess, Hussein A. Tawbi, Ola Myklebost, Trevor Clancy

URL: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1226445/abstract

About NEC OncoImmunity AS

NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. The AI technology can be used to identify optimal antigen/epitope targets for infectious disease vaccines, truly personalized cancer vaccines & Tcell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at http://www.oncoimmunity.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Name: Trevor Clancy, Chief Scientific Officer and Co-founder NEC OncoImmunity
Phone: +47 41431242
Email: trevor@oncoimmunity.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye